Recent Finacing
Recent Raise
Biosight is a clinical‑stage biotech developing cytarabine–asparagine prodrug BST‑236 (aspacytarabine/Astarabine) for AML and MDS, conducting multi‑center Phase 2b trials in the U.S., Israel and planning European studies.
